Similar Papers

Paper Title
Journal
Date
Author
Recombinant Human Adenovirus Type 5 (H101) Intra-Tumor Therapy in Patients with Persistent, Recurrent, or Metastatic Cervical Cancer: Genomic Profiling Relating to Clinical Efficacy.
Qiying Zhang ... Zi Liu
Drug Design, Development and Therapy | VOL. 17
Qiying Zhang, et. al.Qiying Zhang ... Zi Liu
01 Nov 2023
Efficacy and safety of recombinant human adenovirus type 5 (H101) combined with immune checkpoint inhibitors (ICIs) in patients with liver metastatic gastric cancer: A prospective multicenter phase II study (the TROJAN 021 study).
Min Yuan ... Qiong Zhan
Journal of Clinical Oncology | VOL. 42
Min Yuan, et. al.Min Yuan ... Qiong Zhan
01 Jun 2024
Trial in progress: Phase II study of stereotactic body radiation therapy and atezolizumab in the management of recurrent, persistent, or metastatic cervical cancer.
Kamran A Ahmed ... Sachin M Apte
Journal of Clinical Oncology | VOL. 37
Kamran A Ahmed, et. al.Kamran A Ahmed ... Sachin M Apte
20 May 2019
First-Line Treatment With Atezolizumab Plus Bevacizumab and Chemotherapy for US Patients With Metastatic, Persistent, or Recurrent Cervical Cancer: A Cost-Effectiveness Analysis
Jianying Lei ... Na Li
Value in Health | VOL. 27
Jianying Lei, et. al.Jianying Lei ... Na Li
02 Aug 2024
View more papers

More From: Annals of Oncology

Paper Title
Journal
Date
Author
Expanding the role of CDK4/6 inhibitors in early breast cancer: insights from the NATALEE trial
Marcela Carausu ... Michail Ignatiadis
Annals of Oncology | VOL. 36
Marcela Carausu, et. al.Marcela Carausu ... Michail Ignatiadis
01 Feb 2025
Table of Contents
-
Annals of Oncology | VOL. 36
--
01 Feb 2025
Editorial Board
-
Annals of Oncology | VOL. 36
--
01 Feb 2025
Table of Contents
-
Annals of Oncology | VOL. 36
--
01 Jan 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.